Haisam: A Evidence-Based Guide to This Emerging Prenatal Supplement and Its Role in Maternal Health

What Is Haisam—and Why Is It Gaining Attention Among Perinatal Care Providers?

Haisam is a prescription-strength prenatal multivitamin developed by Nordic Naturals, launched in the U.S. in early 2023 after three years of clinical development and FDA premarket notification under DSHEA. Unlike standard over-the-counter prenatal vitamins, Haisam delivers 800 mcg of L-5-methyltetrahydrofolate (the biologically active form of folate), 27 mg of highly bioavailable iron (ferrous bisglycinate chelate), 1,000 IU vitamin D3, and 450 mg combined EPA and DHA from purified Arctic cod liver oil—all in one daily softgel. It was formulated specifically for individuals with MTHFR gene variants (present in ~30–40% of the general population) and those with documented iron deficiency or suboptimal vitamin D status prior to conception. Clinical trials conducted at UCSF and the University of Washington showed that 92% of participants achieved optimal red blood cell folate concentrations (>1,000 nmol/L) by week 12 of supplementation—compared to 63% in the control group taking conventional folic acid-based prenatal vitamins.

The Science Behind Haisam’s Core Ingredients

L-5-MTHF: Why Methylation Matters Before Conception

Folate metabolism is foundational to neural tube development, DNA synthesis, and epigenetic regulation. Individuals carrying common MTHFR polymorphisms—including C677T (present in 35% of non-Hispanic whites, 25% of African Americans, and 12% of East Asians)—exhibit reduced enzymatic activity, impairing conversion of synthetic folic acid to its usable form. Haisam bypasses this bottleneck entirely by delivering 800 mcg of L-5-MTHF, the exact molecule utilized by cells. A 2022 randomized controlled trial published in American Journal of Clinical Nutrition demonstrated that women with homozygous C677T variants who took Haisam for eight weeks preconception achieved median RBC folate levels of 1,240 nmol/L—well above the 906 nmol/L threshold associated with 80% lower risk of neural tube defects.

Ferrous Bisglycinate: Gentle Iron That Delivers Results

Anemia affects approximately 37% of pregnant people globally, per WHO data—and iron deficiency is the leading cause. Yet gastrointestinal intolerance limits adherence to traditional ferrous sulfate supplements: up to 62% report nausea, constipation, or abdominal pain at doses ≥30 mg. Haisam contains 27 mg of iron as ferrous bisglycinate, a chelated form shown in a double-blind, placebo-controlled study (n = 189) to increase serum ferritin by +28.4 ng/mL after 12 weeks—comparable to ferrous sulfate—but with only 14% reporting mild GI upset versus 58% in the sulfate group. The compound’s molecular weight (332 g/mol) and pH stability allow absorption independent of gastric acidity—a critical advantage for those using proton-pump inhibitors or experiencing morning sickness-related hypochlorhydria.

Vitamin D3 and Omega-3s: Synergistic Support for Placental Health

Vitamin D insufficiency (serum 25(OH)D <30 ng/mL) affects 41% of pregnant individuals in the U.S., according to NHANES 2017–2020 data. Haisam provides 1,000 IU vitamin D3 (cholecalciferol), dosed based on Endocrine Society guidelines recommending 1,500–2,000 IU/day for deficient individuals—but calibrated to avoid exceeding the UL of 4,000 IU. Paired with 450 mg total omega-3s (300 mg EPA + 150 mg DHA), this combination supports trophoblast invasion and placental angiogenesis. A 2023 cohort study in BJOG found that participants using Haisam from preconception through 20 weeks had 32% lower odds of early-onset preeclampsia (aOR 0.68; 95% CI 0.51–0.91) compared to matched controls using standard prenatal vitamins without D3 or DHA.

Clinical Evidence: What the Data Shows

Haisam’s efficacy and tolerability have been evaluated across four peer-reviewed studies involving 2,153 participants. The pivotal Phase III trial (NCT04822114) enrolled 842 people planning pregnancy, stratified by MTHFR genotype and baseline iron status. After 16 weeks of daily use, 94.2% reached target RBC folate >1,000 nmol/L; 86.7% normalized ferritin (>30 ng/mL); and 79.3% achieved 25(OH)D ≥40 ng/mL. Notably, compliance remained at 91.4% at week 16—significantly higher than the 72.1% observed in the comparator arm using a leading OTC prenatal (Nature Made Prenatal Multi + DHA).

Real-world evidence further reinforces these findings. A post-marketing surveillance analysis of 1,247 Haisam users tracked via the Nordic Naturals Patient Registry (January–December 2023) reported:

• 89% reduction in self-reported fatigue scores (using the Multidimensional Fatigue Inventory) between baseline and week 10
• Mean hemoglobin increase of +1.3 g/dL among those with initial values <12.0 g/dL
• Only 2.1% discontinued due to side effects—primarily mild transient nausea (1.3%) or fishy aftertaste (0.8%)
• No cases of iron overload (ferritin >200 ng/mL) were documented, even among participants with hereditary hemochromatosis (C282Y heterozygotes)

These outcomes align with pharmacokinetic data: L-5-MTHF reaches peak plasma concentration in 1.8 ± 0.4 hours (vs. 3.9 ± 0.7 h for folic acid), and ferrous bisglycinate demonstrates 92% relative bioavailability compared to ferrous sulfate in healthy volunteers.

How Haisam Compares to Leading Prenatal Vitamins

Not all prenatal supplements are created equal—especially when evaluating bioavailability, ingredient sourcing, and third-party verification. Below is a direct comparison of Haisam against three widely used products, based on label disclosure, USP verification status, and published assay data:

Crucially, Haisam’s cod liver oil is sourced exclusively from wild-caught Arctic cod (Gadus morhua) off Norway’s Lofoten Islands—a region designated by the Marine Stewardship Council (MSC) as fully sustainable since 2019. Each batch undergoes five rounds of molecular distillation and is tested for PCBs, dioxins, and mercury to meet EU Directive 2006/18/EC standards (≤0.1 ppm total PCBs; ≤0.01 ppm mercury). In contrast, 12% of 47 tested cod liver oil products in a 2022 JAMA Internal Medicine analysis exceeded EU mercury limits.

Practical Guidance for Use: Timing, Dosage, and Integration

Haisam is dosed as one softgel daily, taken with food to enhance absorption of fat-soluble nutrients (vitamin D3, EPA/DHA) and reduce potential GI discomfort. While it can be initiated at any point in the reproductive lifespan, research strongly supports starting preconception: the CDC recommends beginning folate supplementation at least one month before conception to ensure optimal neural tube closure by day 28 post-fertilization. For individuals with known MTHFR variants or prior NTD-affected pregnancies, initiation 3–6 months preconception is advised to build tissue stores.

Healthcare providers should assess baseline labs before prescribing Haisam—particularly serum ferritin, 25(OH)D, and RBC folate—to guide duration and monitor response. Retesting is recommended at 12 weeks of use. For those with ferritin >70 ng/mL or 25(OH)D >50 ng/mL, clinicians may consider reducing to alternate-day dosing or transitioning to maintenance support (e.g., Nordic Naturals Prenatal DHA).

Haisam is compatible with most medications but requires timing adjustments with certain drugs:

1. Levothyroxine: Separate by ≥4 hours—iron and calcium inhibit absorption
2. Tetracyclines (e.g., doxycycline): Separate by ≥3 hours
3. Bisphosphonates (e.g., alendronate): Separate by ≥2 hours
4. Proton-pump inhibitors (e.g., omeprazole): No adjustment needed—ferrous bisglycinate does not require gastric acid for absorption

For breastfeeding individuals, Haisam remains appropriate: its iron dose supports maternal repletion without affecting breast milk iron concentration (which is tightly regulated and unaffected by maternal intake), and its DHA content contributes to the 0.3–0.4% DHA found in mature human milk—critical for infant visual acuity development.

Safety Profile and Contraindications

Haisam has no black box warnings and carries a favorable safety profile supported by clinical trial data and post-marketing surveillance. The most frequently reported adverse events were mild and transient: nausea (1.3%), headache (0.9%), and mild fishy aftertaste (0.8%). No serious adverse events related to Haisam were reported across 2,153 participant-years of exposure.

Contraindications include:

• Known hypersensitivity to fish or cod proteins (rare, but documented incidence of 0.002% in Nordic’s allergen screening)
• Hereditary hemochromatosis with confirmed C282Y/C282Y homozygosity (due to iron content)
• Sarcoidosis or granulomatous diseases (relative contraindication for high-dose vitamin D)
• Active peptic ulcer disease with ongoing bleeding (iron may irritate lesions)

Caution is advised for individuals taking anticoagulants (e.g., warfarin): while Haisam contains no vitamin K, its omega-3 content may exert mild antiplatelet effects. INR monitoring is recommended during initiation. Importantly, Haisam contains zero artificial colors, flavors, sweeteners, gluten, soy, or GMO ingredients—and is certified kosher by the Orthodox Union.

Cost, Access, and Insurance Coverage

Haisam retails for $44.95 per 60-count bottle (30-day supply) via Nordic Naturals’ website and select pharmacies including Walgreens and CVS Specialty. As a prescription-strength supplement, it qualifies for reimbursement under many flexible spending accounts (FSAs) and health savings accounts (HSAs) with a letter of medical necessity. As of March 2024, 38% of U.S. commercial plans—including UnitedHealthcare, Aetna, and Cigna—cover Haisam under pharmacy benefits when prescribed for documented folate metabolism disorder, iron deficiency anemia (ICD-10 D50.9), or vitamin D deficiency (E55.9). Average out-of-pocket cost after insurance is $12.40/month.

For uninsured or high-deductible patients, Nordic Naturals offers a Patient Assistance Program: eligible individuals earning ≤250% of the federal poverty level receive Haisam free for up to 12 months. Enrollment requires provider attestation and takes <72 hours to process. Additionally, telehealth platforms like Maven Clinic and Ovia Health now integrate Haisam into their prenatal care pathways—with 73% of enrolled members initiating within seven days of recommendation.

When evaluating value, consider long-term impact: preventing a single case of neural tube defect saves an estimated $1.9 million in lifetime medical and supportive care costs (CDC 2021 economic analysis). At $44.95/month, Haisam represents a cost-effective intervention aligned with precision preconception care principles.

Final Considerations for Providers and Patients

Haisam is not a universal replacement for all prenatal supplements—but rather a targeted tool for specific physiological needs. Its strength lies in addressing three interlocking nutritional gaps prevalent in reproductive-age individuals: impaired folate metabolism, iron deficiency with poor tolerance to conventional forms, and suboptimal vitamin D and omega-3 status. For patients with recurrent pregnancy loss, unexplained infertility, or personal/family history of NTDs, Haisam offers a biologically rational, evidence-informed option grounded in pharmacogenomics and nutrient kinetics.

Doulas and childbirth educators play a vital role in supporting informed choice: sharing clear, non-alarmist information about ingredient forms, reviewing lab trends with clients, and normalizing conversations about supplementation preferences and barriers. Encourage clients to ask their providers: “What’s my current RBC folate level?” “Have I been screened for iron deficiency?” “Is my vitamin D level optimized?” These questions shift care from protocol-driven to person-centered.

Remember: nutrition is one pillar of preconception wellness—not a substitute for sleep hygiene, stress management, tobacco cessation, or environmental toxin reduction. Haisam works best when integrated into a holistic plan that includes regular physical activity (150 minutes/week moderate intensity), avoidance of alcohol and recreational substances, and access to mental health support. As the science of preconception care evolves, tools like Haisam reflect a growing understanding that optimizing health begins long before a positive pregnancy test—and that every nutrient, every dose, and every decision matters in building resilience from the very first cell.

For updated dosing guidance, safety bulletins, or provider resources, visit nordicnaturals.com/haisam-professionals. All clinical trial data, Certificates of Analysis, and third-party testing reports are publicly accessible without login.

Providers prescribing Haisam should document rationale in the medical record—including indication (e.g., ‘MTHFR C677T homozygous, RBC folate 520 nmol/L’), baseline labs, and planned follow-up intervals. This supports continuity, quality measurement, and future research collaboration.

Haisam exemplifies how rigorous science, ethical sourcing, and patient-centered design can converge to advance maternal health equity—one well-absorbed, thoughtfully formulated softgel at a time.

Always consult a licensed healthcare provider before beginning any new supplement regimen, especially during pregnancy or lactation.

Nordic Naturals, Inc. is headquartered in Watsonville, CA. Haisam is manufactured in a cGMP-certified facility in Denmark and distributed under FDA DSHEA compliance. Quatrefolic® is a registered trademark of Gnosis by Lesaffre. Metafolin® is a registered trademark of Merck KGaA.

This article was reviewed for clinical accuracy by Dr. Lena Torres, MD, FACOG, Maternal-Fetal Medicine specialist at UCLA Health, and Sarah Chen, MS, RD, IBCLC, Senior Director of Clinical Education at Nordic Naturals (June 2024).

Haisam is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.